Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Virpax Pharmaceuticals, Inc. - Common Stock (NQ: VRPX )

0.3263 +0.0374 (+12.95%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Virpax Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Virpax Pharmaceuticals Announces Extension of CRADA with the U.S. Army Institute of Surgical Research
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Gerald W. Bruce Appointed President and CEO of Novvae™ Pharmaceuticals
From Virpax Pharmaceuticals
Via Business Wire
Virpax Pharmaceuticals Announces Results of Probudur™ Dose Escalation Studies
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax Pharmaceuticals to Present at the LD Micro Main Event XVI
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Altasciences Chosen by Virpax to Support the Development of a New Drug to Prevent Spread of Flu-like Viruses
From Altasciences
Via Business Wire
Virpax Pharmaceuticals Announces the Formation of Novvae™ Pharmaceuticals
From Virpax Pharmaceuticals
Via Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Virpax Pharmaceuticals Updates on Litigation
From Virpax Pharmaceuticals
Via Business Wire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Virpax® Pharmaceuticals to Present at H.C. Wainwright 25th Annual Global Investment Conference
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax Pharmaceuticals Reports 2023 Second Quarter Results and Recent Developments
From Virpax® Pharmaceuticals, Inc.
Via Business Wire
Virpax Pharmaceuticals Files Provisional Patent Application for NSAID Formulation and Method
From Virpax Pharmaceuticals, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Virpax Pharmaceuticals, Inc. to Ring NASDAQ Closing Bell on July 24, 2023
From Virpax Pharmaceuticals, Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Virpax Pharmaceuticals Files Provisional Patent Application for Intranasal Delivery
From Virpax Pharmaceuticals
Via Business Wire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
We're starting off Wednesday with a breakdown of the biggest pre-market stock movers traders will want to keep an eye on! 
Via InvestorPlace
Virpax Pharmaceuticals Enters into CRADA with the National Advisory Neurological Disorders and Stroke Council
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax Pharmaceuticals Announces CFO Transition
From Virpax Pharmaceuticals
Via Business Wire
Virpax Pharmaceuticals to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax Pharmaceuticals Reports 2023 First Quarter Results and Recent Developments
From Virpax® Pharmaceuticals, Inc.
Via Business Wire
Virpax Pharmaceuticals To Present at Upcoming CB Tech Watch Seminar
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax Pharmaceuticals to Present at Sidoti Virtual Investor Conference May 10-11, 2023
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax Pharmaceuticals Engages Dr. Pardeep Gupta to Assist in Development of Company’s Lead Asset, Probudur™
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax Reports on Progress of Envelta™
From Virpax Pharmaceuticals
Via Business Wire
Virpax Pharmaceuticals Announces Appointment of Barbara A. Ruskin, Ph.D, J.D. to the Board of Directors
From Virpax Pharmaceuticals
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.